Allogene Therapeutics (ALLO) Treasury Shares (2019 - 2026)

Allogene Therapeutics has disclosed Treasury Shares across 8 years of filings, most recently posting $4.7 million for Q1 2026.

• Treasury Shares for Q1 2026 came in at $4.7 million, changed 0.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.7 million (changed 0.44% YoY), and the FY2025 annual result was $16.5 million, up 23.86% from the prior year.
• Treasury Shares came in at $4.7 million for Q1 2026 at Allogene Therapeutics, down from $16.5 million in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $16.5 million in Q4 2025 to a low of $2.4 million in Q2 2024.
• The 5-year median for Treasury Shares is $6.1 million (2022), against an average of $8.3 million.
• Across the five-year window, Treasury Shares surged 146.5% in 2023 and sank 81.27% in 2024, its largest moves.
• Allogene Therapeutics' Treasury Shares stood at $5.5 million in 2022, then surged by 121.73% to $12.2 million in 2023, then gained by 9.55% to $13.3 million in 2024, then gained by 23.86% to $16.5 million in 2025, then plunged by 71.63% to $4.7 million in 2026.
• The last three Treasury Shares figures came in at $4.7 million (Q1 2026), $16.5 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.